Department of in Vitro Diagnostic Reagent, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
J Mol Diagn. 2019 Jul;21(4):677-686. doi: 10.1016/j.jmoldx.2019.03.003. Epub 2019 Apr 23.
The absence of interpretation guidelines and limited data on BRCA1/2 mutations in the Chinese population have impeded the detection of BRCA variants based on next-generation sequencing (NGS) in China. This study was performed to establish a reference system for performance evaluation of BRCA genetic testing and variant interpretation, which includes interpretation rules, reference materials (RMs), and a reference database (RD). BRCA1/2 mutations identified in cell lines and clinical cases were selected to establish RMs. All mutations were detected by NGS and validated by Sanger sequencing. Variant call format files and standard variant data sets were collected and annotated to build the RD. Participant laboratories were invited to validate this reference system. Interpretation rules for BRCA variants in the Chinese population were generated as a standard for BRCA variant interpretation. Mutational analysis demonstrated that BRCA2 mutations (55%) were more common than BRCA1 mutations (45%) in Chinese patients. Eliminating duplicates from 19,886 variants, the RD contained 750 unique BRCA mutations. Most BRCA1/2 mutations in the reference system were pathogenic or likely pathogenic (RMs, 77.5%; RD, 57%). In total, 91 novel pathogenic/likely pathogenic variants were identified in the RD. The reference system can contribute to NGS performance and high-quality interpretation to facilitate clinical decision making. It could also accelerate the development and application of BRCA mutation detection technologies in China.
在中国,由于缺乏解释性指导方针和关于 BRCA1/2 突变的有限数据,基于下一代测序(NGS)的 BRCA 变体检测受到了阻碍。本研究旨在建立 BRCA 基因检测和变异解释的性能评估参考系统,该系统包括解释规则、参考材料(RMs)和参考数据库(RD)。选择细胞系和临床病例中鉴定的 BRCA1/2 突变来建立 RMs。所有突变均通过 NGS 检测,并通过 Sanger 测序验证。收集并注释变体调用格式文件和标准变体数据集,以构建 RD。邀请参与者实验室验证该参考系统。为 BRCA 变体在中国人群中的解释生成解释规则,作为 BRCA 变体解释的标准。突变分析表明,中国患者的 BRCA2 突变(55%)比 BRCA1 突变(45%)更为常见。从 19886 个变体中消除重复项后,RD 包含 750 个独特的 BRCA 突变。参考系统中的大多数 BRCA1/2 突变均为致病性或可能致病性(RMs,77.5%;RD,57%)。总共在 RD 中鉴定出 91 个新的致病性/可能致病性变体。该参考系统有助于 NGS 性能和高质量解释,以促进临床决策。它还可以加速中国 BRCA 突变检测技术的发展和应用。